AU2018280742B2 - Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis - Google Patents

Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis Download PDF

Info

Publication number
AU2018280742B2
AU2018280742B2 AU2018280742A AU2018280742A AU2018280742B2 AU 2018280742 B2 AU2018280742 B2 AU 2018280742B2 AU 2018280742 A AU2018280742 A AU 2018280742A AU 2018280742 A AU2018280742 A AU 2018280742A AU 2018280742 B2 AU2018280742 B2 AU 2018280742B2
Authority
AU
Australia
Prior art keywords
day
patient
administered
weeks
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018280742A
Other languages
English (en)
Other versions
AU2018280742A1 (en
Inventor
Jean-Pierre Gotteland
Ernest Loumaye
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kissei Pharmaceutical Co Ltd
Original Assignee
Kissei Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kissei Pharmaceutical Co Ltd filed Critical Kissei Pharmaceutical Co Ltd
Publication of AU2018280742A1 publication Critical patent/AU2018280742A1/en
Assigned to KISSEI PHARMACEUTICAL CO., LTD. reassignment KISSEI PHARMACEUTICAL CO., LTD. Request for Assignment Assignors: ObsEva S.A.
Application granted granted Critical
Publication of AU2018280742B2 publication Critical patent/AU2018280742B2/en
Priority to AU2024201701A priority Critical patent/AU2024201701B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
AU2018280742A 2017-06-05 2018-06-05 Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis Active AU2018280742B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024201701A AU2024201701B2 (en) 2017-06-05 2024-03-14 Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762515268P 2017-06-05 2017-06-05
US62/515,268 2017-06-05
PCT/EP2018/064768 WO2018224498A1 (en) 2017-06-05 2018-06-05 Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024201701A Division AU2024201701B2 (en) 2017-06-05 2024-03-14 Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis

Publications (2)

Publication Number Publication Date
AU2018280742A1 AU2018280742A1 (en) 2020-01-30
AU2018280742B2 true AU2018280742B2 (en) 2023-12-21

Family

ID=62620835

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018280742A Active AU2018280742B2 (en) 2017-06-05 2018-06-05 Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis
AU2024201701A Active AU2024201701B2 (en) 2017-06-05 2024-03-14 Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024201701A Active AU2024201701B2 (en) 2017-06-05 2024-03-14 Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis

Country Status (12)

Country Link
US (2) US11980621B2 (enExample)
EP (1) EP3634418A1 (enExample)
JP (2) JP7348171B2 (enExample)
KR (2) KR102839190B1 (enExample)
CN (1) CN110996956A (enExample)
AU (2) AU2018280742B2 (enExample)
CA (1) CA3066190A1 (enExample)
EA (1) EA201992612A1 (enExample)
MA (1) MA49256A (enExample)
MX (1) MX2019014483A (enExample)
SG (1) SG11201911598WA (enExample)
WO (1) WO2018224498A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202200254T1 (it) 2016-09-30 2022-07-21 Takeda Pharmaceuticals Co Metodi di trattamento di fibromi uterini ed endometriosi
EP3634418A1 (en) 2017-06-05 2020-04-15 ObsEva S.A. Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis
US11759464B2 (en) 2017-06-05 2023-09-19 Kissei Pharmaceutical Co., Ltd. Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss
WO2020089190A2 (en) 2018-10-29 2020-05-07 ObsEva S.A. Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis
KR20220061120A (ko) * 2019-08-08 2022-05-12 옵스에파 에스에이 에스트로겐-의존성 장애 치료용 조성물 및 방법
CN113384581B (zh) * 2020-03-12 2023-11-14 成都倍特药业股份有限公司 一种包含促性腺激素释放激素拮抗剂的药物组合物
MX2022015003A (es) 2020-05-29 2023-03-03 Myovant Sciences Gmbh Formas de dosificacion oral solidas de combinacion de antagonistas de la hormona liberadora de gonadotropina.
WO2022101303A1 (en) * 2020-11-11 2022-05-19 Myovant Sciences Gmbh Methods of administering relugolix
WO2022179469A1 (zh) * 2021-02-23 2022-09-01 南京明德新药研发有限公司 噻吩并嘧啶二酮类化合物及其应用
CN115232144B (zh) * 2021-04-22 2024-04-02 长春金赛药业有限责任公司 含氮稠环类衍生物、药物组合物及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018030317A1 (ja) * 2016-08-08 2018-02-15 キッセイ薬品工業株式会社 子宮内膜症治療剤の用法・用量

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342760A (en) 1992-06-10 1994-08-30 Abbott Laboratories Determination of estradiol by competitive immunoassay
US5663054A (en) 1995-03-03 1997-09-02 Abbott Laboratories Determination of steroids by competitive immunoassay
US7109171B2 (en) 2000-02-28 2006-09-19 Praecis Pharmaceuticals Inc. Methods for treating FSH related conditions with GnRH antagonists
WO2002002533A1 (en) 2000-07-05 2002-01-10 Yamanouchi Pharmaceutical Co., Ltd. Propane-1,3-dione derivatives
ZA200506611B (en) 2003-01-29 2006-12-27 Takeda Pharmaceutical Thienopyrimidine compounds and use thereof
WO2005007165A1 (en) 2003-07-07 2005-01-27 Neurocrine Biosciences, Inc. Pyrimidine-2, 4-dione derivatives as gonadotropin-releasing hormone receptor antagonists
EP1864976B1 (en) 2005-03-31 2012-10-10 Astellas Pharma Inc. Propane-1,3-dion derivative or salt thereof
PT1939204E (pt) * 2005-10-19 2013-03-14 Kissei Pharmaceutical Derivado heterocíclico fundido, composição medicinal contendo o mesmo, e sua utilização medicinal
US8765948B2 (en) 2007-11-07 2014-07-01 Neurocrine Biosciences, Inc. Processes for the preparation of uracil derivatives
EP2535342B1 (en) 2010-02-10 2014-08-06 Kissei Pharmaceutical Co., Ltd. Salt of fused heterocyclic derivative and crystal thereof
CN104169287A (zh) 2012-01-16 2014-11-26 拜耳知识产权有限责任公司 作为促性腺激素释放激素受体拮抗剂的螺二氢吲哚衍生物
WO2013126517A1 (en) 2012-02-21 2013-08-29 Northwestern University Anti-mullerian hormone detection in whole blood
KR20150048762A (ko) 2012-09-07 2015-05-07 아스텔라스세이야쿠 가부시키가이샤 술포닐아미딘 화합물의 제조법
JP6268093B2 (ja) 2012-09-14 2018-01-24 キッセイ薬品工業株式会社 縮合複素環誘導体の製造方法およびその製造中間体
SMT202200255T1 (it) 2012-09-28 2022-07-21 Takeda Pharmaceuticals Co Forma cristallina di 1-(4-1-(2,6-difluorobenzil)-5-dimetilamminometil-3-(6-metossipiridazin-3-il)-2,4-diosso-1,2,3,4-tetraidrotieno(2,3-d)-pirimidin-6il)fenil)-3-metossiurea
IL241595B2 (en) 2013-03-15 2025-10-01 Abbvie Inc Composition for use in methods of treating heavy menstrual bleeding associated with uterine fibroids
AR095785A1 (es) 2013-04-09 2015-11-11 Bayer Pharma AG Derivados de espiroindolina y composiciones farmacéutica de los mismos
CA3002791A1 (en) 2015-09-01 2017-03-09 Abbvie Inc. Methods of administering elagolix
SMT202200254T1 (it) 2016-09-30 2022-07-21 Takeda Pharmaceuticals Co Metodi di trattamento di fibromi uterini ed endometriosi
US11759464B2 (en) 2017-06-05 2023-09-19 Kissei Pharmaceutical Co., Ltd. Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss
EP3634418A1 (en) 2017-06-05 2020-04-15 ObsEva S.A. Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis
KR20210100623A (ko) 2018-11-07 2021-08-17 옵스에파 에스에이 에스트로겐-의존성 장애의 치료를 위한 조성물 및 방법

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018030317A1 (ja) * 2016-08-08 2018-02-15 キッセイ薬品工業株式会社 子宮内膜症治療剤の用法・用量

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JACQUES DONNEZ: "Partial suppression of estradiol: a new strategy in endometriosis management?", FERTILITY AND STERILITY, 1 March 2017, pages 568 - 570. *
OBSEVA: "Annual Report 2106". Published 21 February 2017. *

Also Published As

Publication number Publication date
JP2020522571A (ja) 2020-07-30
WO2018224498A1 (en) 2018-12-13
AU2024201701A1 (en) 2024-04-04
KR20250117836A (ko) 2025-08-05
KR102839190B1 (ko) 2025-07-28
MA49256A (fr) 2021-05-26
MX2019014483A (es) 2020-08-17
US11980621B2 (en) 2024-05-14
EP3634418A1 (en) 2020-04-15
AU2018280742A1 (en) 2020-01-30
CN110996956A (zh) 2020-04-10
JP7348171B2 (ja) 2023-09-20
US20200138819A1 (en) 2020-05-07
KR20200027481A (ko) 2020-03-12
JP2023113715A (ja) 2023-08-16
AU2024201701B2 (en) 2025-04-10
CA3066190A1 (en) 2018-12-13
SG11201911598WA (en) 2020-01-30
US20240293414A1 (en) 2024-09-05
JP7657855B2 (ja) 2025-04-07
EA201992612A1 (ru) 2020-05-20

Similar Documents

Publication Publication Date Title
AU2024201701B2 (en) Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis
AU2024201694A1 (en) Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss
WO2020094698A2 (en) Compositions and methods for the treatment of estrogen-dependent disorders
AU2020325721A1 (en) GnRH antagonists for the treatment of estrogen-dependent disorders
WO2021023877A2 (en) Compositions and methods for the treatment of estrogen-dependent disorders
AU2019373349B2 (en) Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis
EA044130B1 (ru) Схемы применения антагониста гонадотропин-высвобождающего гормона для лечения эндометриоза
HK40116843A (en) Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss
EA049129B1 (ru) Схемы применения антагониста гонадотропин-высвобождающего гормона для лечения миомы матки и уменьшения менструальной кровопотери
HK40027583B (en) Dosing regimen comprising a gonadotropin-releasing hormone antagonist for treating uterine fibroids and reducing menstrual blood loss
HK40027583A (en) Dosing regimen comprising a gonadotropin-releasing hormone antagonist for treating uterine fibroids and reducing menstrual blood loss

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: KISSEI PHARMACEUTICAL CO., LTD.

Free format text: FORMER APPLICANT(S): OBSEVA S.A.

FGA Letters patent sealed or granted (standard patent)